301 related articles for article (PubMed ID: 31754172)
21. A-Kinase Anchoring Protein 13 (AKAP13) Augments Progesterone Signaling in Uterine Fibroid Cells.
Ng SSM; Jorge S; Malik M; Britten J; Su SC; Armstrong CR; Brennan JT; Chang S; Baig KM; Driggers PH; Segars JH
J Clin Endocrinol Metab; 2019 Mar; 104(3):970-980. PubMed ID: 30239831
[TBL] [Abstract][Full Text] [Related]
22. Measurement of changes in uterine and fibroid volume during treatment of heavy menstrual bleeding (HMB).
Yin K; Whitaker L; Hojo E; McLenachan S; Walker J; McKillop G; Stubbs C; Priest L; Cruz M; Roberts N; Critchley H
Hum Reprod Open; 2023; 2023(3):hoad021. PubMed ID: 37304815
[TBL] [Abstract][Full Text] [Related]
23. 1,25 Dihydroxyvitamin D3 Enhances the Antifibroid Effects of Ulipristal Acetate in Human Uterine Fibroids.
Ali M; Shahin SM; Sabri NA; Al-Hendy A; Yang Q
Reprod Sci; 2019 Jun; 26(6):812-828. PubMed ID: 30514160
[TBL] [Abstract][Full Text] [Related]
24. Vilaprisan, a New Selective Progesterone Receptor Modulator in Uterine Fibroid Pharmacotherapy-Will it Really be a Breakthrough?
Ciebiera M; Vitale SG; Ferrero S; Vilos GA; Barra F; Caruso S; Laganà AS; Sierant A; Cianci A; Jakiel G
Curr Pharm Des; 2020; 26(3):300-309. PubMed ID: 31985366
[TBL] [Abstract][Full Text] [Related]
25. Application of ulipristal acetate in female patients with uterine fibroids.
Grzechocinska B; Gadomska H; Zygula A; Wielgos M
Neuro Endocrinol Lett; 2014; 35(3):175-8. PubMed ID: 24977963
[TBL] [Abstract][Full Text] [Related]
26. Ulipristal acetate versus placebo for fibroid treatment before surgery.
Donnez J; Tatarchuk TF; Bouchard P; Puscasiu L; Zakharenko NF; Ivanova T; Ugocsai G; Mara M; Jilla MP; Bestel E; Terrill P; Osterloh I; Loumaye E;
N Engl J Med; 2012 Feb; 366(5):409-20. PubMed ID: 22296075
[TBL] [Abstract][Full Text] [Related]
27. Long-term treatment of uterine fibroids with ulipristal acetate ☆.
Donnez J; Vázquez F; Tomaszewski J; Nouri K; Bouchard P; Fauser BC; Barlow DH; Palacios S; Donnez O; Bestel E; Osterloh I; Loumaye E;
Fertil Steril; 2014 Jun; 101(6):1565-73.e1-18. PubMed ID: 24630081
[TBL] [Abstract][Full Text] [Related]
28. Ulipristal acetate: a novel option for the medical management of symptomatic uterine fibroids.
Talaulikar VS; Manyonda IT
Adv Ther; 2012 Aug; 29(8):655-63. PubMed ID: 22903240
[TBL] [Abstract][Full Text] [Related]
29. Ulipristal acetate for use in moderate to severe symptoms of uterine fibroids.
Talaulikar VS; Manyonda I
Womens Health (Lond); 2014 Nov; 10(6):565-70. PubMed ID: 25482483
[TBL] [Abstract][Full Text] [Related]
30. Changes in proliferating and apoptotic markers of leiomyoma following treatment with a selective progesterone receptor modulator or gonadotropin-releasing hormone agonist.
Yun BS; Seong SJ; Cha DH; Kim JY; Kim ML; Shim JY; Park JE
Eur J Obstet Gynecol Reprod Biol; 2015 Aug; 191():62-7. PubMed ID: 26093349
[TBL] [Abstract][Full Text] [Related]
31. The past, present, and future of selective progesterone receptor modulators in the management of uterine fibroids.
Singh SS; Belland L; Leyland N; von Riedemann S; Murji A
Am J Obstet Gynecol; 2018 Jun; 218(6):563-572.e1. PubMed ID: 29274830
[TBL] [Abstract][Full Text] [Related]
32. Ulipristal acetate in the management of symptomatic uterine fibroids: facts and pending issues.
Pérez-López FR
Climacteric; 2015 Apr; 18(2):177-81. PubMed ID: 25390187
[TBL] [Abstract][Full Text] [Related]
33. The place of selective progesterone receptor modulators in myoma therapy.
Donnez J; Donnez O; Courtoy GE; Dolmans MM
Minerva Ginecol; 2016 Jun; 68(3):313-20. PubMed ID: 26930390
[TBL] [Abstract][Full Text] [Related]
34. Ulipristal acetate before in vitro fertilization: efficacy in infertile women with submucous fibroids.
Morgante G; Centini G; Troìa L; Orvieto R; De Leo V
Reprod Biol Endocrinol; 2020 May; 18(1):50. PubMed ID: 32430027
[TBL] [Abstract][Full Text] [Related]
35. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata.
Williams AR; Critchley HO; Osei J; Ingamells S; Cameron IT; Han C; Chwalisz K
Hum Reprod; 2007 Jun; 22(6):1696-704. PubMed ID: 17339234
[TBL] [Abstract][Full Text] [Related]
36. Ulipristal acetate compared with leuprorelin acetate for Japanese women with symptomatic uterine fibroids: a phase III randomized controlled trial.
Osuga Y; Nakano Y; Yamauchi Y; Takanashi M
Fertil Steril; 2021 Jul; 116(1):189-197. PubMed ID: 33715871
[TBL] [Abstract][Full Text] [Related]
37. The Selective Progesterone Receptor Modulator Ulipristal Acetate Inhibits the Activity of the Glucocorticoid Receptor.
Small B; Millard CEF; Kisanga EP; Burman A; Anam A; Flannery C; Al-Hendy A; Whirledge S
J Clin Endocrinol Metab; 2020 Mar; 105(3):716-34. PubMed ID: 31665442
[TBL] [Abstract][Full Text] [Related]
38. Fibroid management in premenopausal women.
Donnez J; Courtoy GE; Dolmans MM
Climacteric; 2019 Feb; 22(1):27-33. PubMed ID: 30601065
[TBL] [Abstract][Full Text] [Related]
39. Place of ulipristal acetate in the management of uterine fibroids: Preoperative treatment or sequential treatment?
Pourcelot AG; Capmas P; Fernandez H
J Gynecol Obstet Hum Reprod; 2017 Mar; 46(3):249-254. PubMed ID: 28403922
[TBL] [Abstract][Full Text] [Related]
40. Selective Progesterone Receptor Modulators for the Medical Treatment of Uterine Fibroids with a Focus on Ulipristal Acetate.
Rabe T; Saenger N; Ebert AD; Roemer T; Tinneberg HR; De Wilde RL; Wallwiener M
Biomed Res Int; 2018; 2018():1374821. PubMed ID: 30539001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]